Snapshot from Jul 23, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / ARS Pharmaceuticals Securities Investigation
Regulatory securities investigation

ARS Pharmaceuticals Securities Investigation

Analysis based on 13 articles · First reported Jun 26, 2026 · Last updated Jul 01, 2026

Sentiment
-50
Attention
4
Articles
13
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The market is negatively impacted by the investigation into ARS Pharmaceuticals, as its stock price fell over 23% due to the disclosure of Neffy's lack of new formulary additions. This event highlights the risks associated with pharmaceutical companies' product commercialization and the potential for legal action against companies for misleading investor statements.

Pharmaceuticals Legal Services
Event Summary

Levi & Korsinsky has initiated an investigation into ARS Pharmaceuticals for potential violations of federal securities laws. This follows a more than 23% drop in ARS Pharmaceuticals' stock price on June 24, 2026, after the company disclosed that its epinephrine nasal spray, Neffy, received no new commercial formulary additions or payer-coverage decisions in the July 1, 2026 review cycle. The investigation focuses on allegedly misleading statements made by CEO Richard Löwenthal and Chief Commercial Officer Eric Karas regarding Neffy's anticipated commercial coverage and formulary inclusions with entities like CVS Health, Elevance Health, and CVS Health — Aetna.

Key Actions
100 Levi & Korsinsky commenced investigation ARS Pharmaceuticals
90 ARS Pharmaceuticals disclosed zero additions
80 Richard Löwenthal projected coverage
70 Eric Karas stated goal
60 Richard Löwenthal characterized slowdown
Entities Involved
priv
ARS Pharmaceuticals
ARS Pharmaceuticals is under investigation for potential violations of federal securities laws due to allegedly misleading statements regarding Neffy's commercial coverage, which led to a significant stock price drop.
Importance 100.0 Sentiment -70.0
oth
Neffy
Neffy is ARS Pharmaceuticals' flagship epinephrine nasal spray, whose lack of new commercial formulary additions triggered the investigation and the company's stock decline.
Importance 90.0 Sentiment -40.0
priv
Levi & Korsinsky
Levi & Korsinsky is a securities litigation firm that initiated the investigation into ARS Pharmaceuticals and is actively seeking investors who suffered losses to represent them in a potential lawsuit.
Importance 80.0 Sentiment 60.0
per
Richard Löwenthal
Richard Löwenthal, CEO of ARS Pharmaceuticals, made several projections about Neffy's formulary coverage that are now under scrutiny as part of the securities investigation.
Importance 70.0 Sentiment -60.0
per
Eric Karas
Eric Karas, Chief Commercial Officer of ARS Pharmaceuticals, also made projections about Neffy's commercial coverage that are being investigated for potential misleading statements.
Importance 50.0 Sentiment -50.0
stock
CVS Health
CVS Health was specifically mentioned by ARS Pharmaceuticals' management as a key formulary addition expected by July 1, 2026, which did not materialize, contributing to the investigation.
Importance 40.0 Sentiment 0.0
subs
Cigna — Express Scripts
Cigna — Express Scripts was one of the entities with whom ARS Pharmaceuticals had already secured coverage for Neffy, as stated by CEO Richard Löwenthal.
Importance 20.0 Sentiment 0.0
subs
UnitedHealth Group — UnitedHealth Group
UnitedHealth Group — UnitedHealth Group was one of the entities with whom ARS Pharmaceuticals had already secured coverage for Neffy, as stated by CEO Richard Löwenthal.
Importance 20.0 Sentiment 0.0
stock
Elevance Health
Elevance Health was anticipated by ARS Pharmaceuticals' management to add Neffy to its formulary by July 1, 2026, which did not occur.
Importance 20.0 Sentiment 0.0
subs
CVS Health — Aetna
CVS Health — Aetna was anticipated by ARS Pharmaceuticals' management to add Neffy to its formulary by July 1, 2026, which did not occur.
Importance 20.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.